Search
Streptococcus pneumoniae type 4 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10322ApprovedInvestigationalStreptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 5 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10323ApprovedInvestigationalStreptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 15b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10333ApprovedInvestigationalStreptococcus pneumoniae type 15b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 15b of *Streptococcus pneumoniae
Streptococcus pneumoniae type 17f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10334ApprovedInvestigationalStreptococcus pneumoniae type 17f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 17f of *Streptococcus pneumoniae
Streptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalStreptococcus pneumoniae type 19a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19a of *Streptococcus pneumoniae
Streptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalStreptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of *Streptococcus pneumoniae
Prolectin-M
go.drugbank.com/drugs/DB16521Investigational[L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Cetrelimab
go.drugbank.com/drugs/DB15421InvestigationalCetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD
Piretanide
go.drugbank.com/drugs/DB02925Approvednames Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the
POT-4
go.drugbank.com/drugs/DB06056InvestigationalPOT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).